Miniatura

Fitxers

jcm-10-02642-v3.pdf (3.88 MB)

Tipus de document

Article

Versió

Versió publicada

Data de publicació

2021-06-15

Llicència de publicació

cc by (c) Roy Vallejo, Emilia et al., 2021
Si us plau utilitzeu sempre aquest identificador per citar o enllaçar aquest document: https://hdl.handle.net/2445/179215

Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers Withdrawal Is Associated with Higher Mortality in Hospitalized Patients with COVID-19

Títol de la revista

Autors

Director/Tutor

ISSN de la revista

Títol del volum

Recurs relacionat

https://doi.org/10.3390/jcm10122642

Resum

Our main aim was to describe the effect on the severity of ACEI (angiotensin-converting enzyme inhibitor) and ARB (angiotensin II receptor blocker) during COVID-19 hospitalization. A retrospective, observational, multicenter study evaluating hospitalized patients with COVID-19 treated with ACEI/ARB. The primary endpoint was the incidence of the composite outcome of prognosis (IMV (invasive mechanical ventilation), NIMV (non-invasive mechanical ventilation), ICU admission (intensive care unit), and/or all-cause mortality). We evaluated both outcomes in patients whose treatment with ACEI/ARB was continued or withdrawn. Between February and June 2020, 11,205 patients were included, mean age 67 years (SD = 16.3) and 43.1% female; 2162 patients received ACEI/ARB treatment. ACEI/ARB treatment showed lower all-cause mortality (p < 0.0001). Hypertensive patients in the ACEI/ARB group had better results in IMV, ICU admission, and the composite outcome of prognosis (p < 0.0001 for all). No differences were found in the incidence of major adverse cardiovascular events. Patients previously treated with ACEI/ARB continuing treatment during hospitalization had a lower incidence of the composite outcome of prognosis than those whose treatment was withdrawn (RR 0.67, 95%CI 0.63-0.76). ARB was associated with better survival than ACEI (HR 0.77, 95%CI 0.62-0.96). ACEI/ARB treatment during COVID-19 hospitalization was associated with protection on mortality. The benefits were greater in hypertensive, those who continued

Matèries

COVID-19, Hospitals, Pacients hospitalitzats, Pronòstic mèdic

Matèries (anglès)

COVID-19, Hospitals, Hospital patients, Prognosis

Citació

Col·leccions

Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL))

Citació

ROY VALLEJO, Emilia, SÁNCHEZ PURIFICACIÓN, Aquilino, TORRES PEÑA, José, SÁNCHEZ MORENO, Beatriz, ARNALICH FERNÁNDEZ, Francisco, GARCÍA BLANCO, María, LÓPEZ MIRANDA, José, ROMERO CABRERA, Juan luis, HERRERO GIL, Carmen, BASCUNANA, José, RUBIO-RIVAS, Manuel, PINTOS OTERO, Sara, MARTÍNEZ SEMPERE, Verónica, BALLANO RODRÍGUEZ-SOLÍS, Jesús, GIL SÁNCHEZ, Ricardo, LUQUE DEL PINO, Jairo, GONZÁLEZ NOYA, Amara, NAVAS ALCÁNTARA, María, CORTÉS RODRÍGUEZ, Begoña, ALCALÁ, José, SUÁREZ LOMBRAÑA, Ana, ANDRÉS SOLER, Jorge, GÓMEZ HUELGAS, Ricardo, CASAS ROJO, José, MILLÁN NÚÑEZ-CORTÉS, Jesús, SEMI-COVID-19 Network. Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers Withdrawal Is Associated with Higher Mortality in Hospitalized Patients with COVID-19. _Journal of Clinical Medicine_. 2021. Vol. 10, núm. 12, pàgs. 2642. [consulta: 23 de gener de 2026]. ISSN: 2077-0383. [Disponible a: https://hdl.handle.net/2445/179215]

Exportar metadades

JSON - METS

Compartir registre